{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:47:46Z","timestamp":1793342866961,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n West Nile virus (WNV) is the leading mosquito-borne infection in the US, causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality. Contemporary analyses are needed to identify at-risk populations and to target interventions.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess risk factors associated with WNND and mortality among adults with WNV infection using a national cohort from federated data.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study of deidentified electronic medical record data from the TriNetX research network from January 2013 to December 2024 included patients from 65 health care organizations from across the US. Data were accessed from March 28 to April 30, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Demographic characteristics (age, sex, race, and ethnicity), comorbidities (hematologic malignant neoplasms, heart disease, diabetes, HIV infection, chronic kidney disease [CKD], liver disease, hypertension, alcohol-related disorders, cerebrovascular disease [CEVD], chronic obstructive pulmonary disease, asthma, multiple sclerosis, dementia, rheumatoid arthritis, and organ transplant), and medications (immune suppressants, antineoplastics).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were WNND development and all-cause mortality (at 30 days, 90 days, and overall).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the initial cohort of 3064 patients with a diagnosis of WNV infection (per the\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n codes), those with demographic data included 1249 (53%) who were consistent with West Nile fever (624 females [50%]; mean [SD] age, 55 [17] years) and 1127 (47%) who were consistent with WNND (691 males [61%]; mean [SD] age, 59 [17] years). Risk factors associated with WNND included age (adjusted hazard ratio [AHR], 1.10 [95% CI, 1.06-1.15] per decade), male sex (AHR, 1.29 [95% CI, 1.15-1.45]), CKD (AHR, 1.21 [95% CI, 1.00-1.45]), CEVD (AHR, 1.22 [95% CI, 1.03-1.45]), hematologic malignant neoplasms (AHR, 1.38 [95% CI, 1.09-1.76]), immune suppressant use (AHR, 1.43 [95% CI, 1.11-1.83]), hypertension (AHR, 1.18 [95% CI, 1.04-1.34]), alcohol-related disorders (AHR, 1.54 [95% CI, 1.20-1.97]), and multiple sclerosis (AHR, 2.34 [95% CI, 1.62-3.37]). Significant risk factors associated with mortality were WNND (AHR, 2.49 [95% CI, 1.37-4.52] for 30-day mortality), age (AHR, 1.32 [95% CI, 1.07-1.60] per decade), CKD (AHR, 2.08 [95% CI, 1.01-3.93]), and CEVD (AHR, 2.00 [95% CI, 1.14-3.50]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with WNV infection, multiple comorbidities were identified as risk factors associated with WNND; and patients who developed WNND had increased mortality risk. Targeted prevention strategies and countermeasures for high-risk individuals may substantially reduce morbidity and mortality.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.48229","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:37Z","timestamp":1765382437000},"page":"e2548229","source":"Crossref","is-referenced-by-count":9,"title":["Risk Factors for West Nile Neuroinvasive Disease and Mortality in the US, 2013-2024"],"prefix":"10.1001","volume":"8","author":[{"given":"Seth D.","family":"Judson","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dowdy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"6","key":"zoi251298r2","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jme\/tjz085","article-title":"Epidemiology of West Nile virus in the United States: implications for arbovirology and public health.","volume":"56","author":"Petersen","year":"2019","journal-title":"J Med Entomol"},{"issue":"9","key":"zoi251298r3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1086\/656602","article-title":"West Nile fever characteristics among viremic persons identified through blood donor screening.","volume":"202","author":"Zou","year":"2010","journal-title":"J Infect Dis"},{"issue":"12","key":"zoi251298r4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1086\/518281","article-title":"The long-term outcomes of human West Nile virus infection.","volume":"44","author":"Sejvar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi251298r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7001a1","article-title":"Surveillance for West Nile virus disease\u2014United States, 2009-2018.","volume":"70","author":"McDonald","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"zoi251298r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2020.100105","article-title":"Long-term, West Nile virus-induced neurological changes: a comparison of patients and rodent models.","volume":"7","author":"Fulton","year":"2020","journal-title":"Brain Behav Immun Health"},{"issue":"1","key":"zoi251298r7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12879-017-2637-9","article-title":"Epidemiologic and clinical parameters of West Nile virus infections in humans: a scoping review.","volume":"17","author":"Yeung","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"zoi251298r8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4269\/ajtmh.2012.12-0113","article-title":"Medical risk factors for severe West Nile virus disease, United States, 2008-2010.","volume":"87","author":"Lindsey","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"zoi251298r9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.27220","article-title":"Clinical, prognostic, and longitudinal functional and neuropsychological features of West Nile virus neuroinvasive disease in the United States: a systematic review and meta-analysis.","volume":"98","author":"Roberts","year":"2025","journal-title":"Ann Neurol"},{"issue":"3","key":"zoi251298r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4294","article-title":"Neuroinvasive West Nile virus infection in immunosuppressed and immunocompetent adults.","volume":"7","author":"Mbonde","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251298r11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1186\/s12879-024-10230-5","article-title":"Federated learning as a smart tool for research on infectious diseases.","volume":"24","author":"Zwiers","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"2","key":"zoi251298r12","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"zoi251298r14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"zoi251298r15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11908-011-0193-9","article-title":"West Nile virus neuroinvasive disease.","volume":"13","author":"Debiasi","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"zoi251298r16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-4939-3670-0","article-title":"In vitro and in vivo blood-brain barrier models to study West Nile virus pathogenesis.","volume":"1435","author":"Kumar","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"1","key":"zoi251298r17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13071-022-05630-y","article-title":"Evaluation of an open forecasting challenge to assess skill of West Nile virus neuroinvasive disease prediction.","volume":"16","author":"Holcomb","year":"2023","journal-title":"Parasit Vectors"},{"issue":"18","key":"zoi251298r18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJMp2301816","article-title":"Combating West Nile virus disease\u2014time to revisit vaccination.","volume":"388","author":"Gould","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi251298r19","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/cid\/ciab540","article-title":"Cost-effectiveness and impact of a targeted age- and incidence-based West Nile virus vaccine strategy.","volume":"73","author":"Curren","year":"2021","journal-title":"Clin Infect Dis"},{"key":"zoi251298r20","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268822000887","article-title":"Comorbid conditions as risk factors for West Nile neuroinvasive disease in Ontario, Canada: a population-based cohort study.","volume":"150","author":"Sutinen","year":"2022","journal-title":"Epidemiol Infect"},{"issue":"2","key":"zoi251298r21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3201\/eid2502.181250","article-title":"Acute and delayed deaths after West Nile virus infection, Texas, USA, 2002-2012.","volume":"25","author":"Philpott","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"zoi251298r23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research.","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"},{"key":"zoi251298r22","author":"Zafar"},{"key":"zoi251298r1","unstructured":"Vector-borne diseases: National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People. US Centers for Disease Control and Prevention. February 13, 2025. Accessed October 29, 2025. https:\/\/www.cdc.gov\/vector-borne-diseases\/php\/data-research\/national-strategy\/index.html"},{"key":"zoi251298r13","unstructured":"West Nile virus: historic data (1999-2024). US Centers for Disease Control and Prevention. June 10, 2025. Accessed October 29, 2025. https:\/\/www.cdc.gov\/west-nile-virus\/data-maps\/historic-data.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842586\/judson_2025_oi_251298_1764800081.52208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:38Z","timestamp":1765382438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.48229","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}